NASDAQ: ONCY · Life Sciences · 10 alerts · CIK 1129928
Share price
$0.3399Close, Nov 16
Market cap
$46.3M
Shares outstanding
136.14MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Oncolytics Biotech Inc filings on SEC EDGAR ↗
Oncolytics Biotech Inc. reported a net loss of $28.4 million for the nine months ended September 30, 2026, compared to $19.9 million in the prior year period, driven by increased R&D and G&A expenses. The company's cash position decreased to $2.4 million, leading management to issue a going concern warning as existing resources are insufficient to fund operations for the next twelve months.
Oncolytics Biotech Research Collaboration with Coherus Oncology, Inc.
Oncolytics Biotech entered into a clinical supply agreement with Coherus Oncology to evaluate pelareorep in combination with LOQTORZI (toripalimab-tpzi) for the treatment of squamous cell anal carcinoma (SCAC). The clinical study, expected to begin in Q1 2027, will target second-line patients who have progressed on standard-of-care treatments.
Oncolytics Biotech announced translational data from a Phase 1b/2 trial evaluating pelareorep in patients with relapsed/refractory multiple myeloma. Single-cell sequencing demonstrated that pelareorep engaged the immune system, remodeled the tumor microenvironment, and increased populations of CD8 effector memory T cells. The data, which showed greater T cell expansion in clinical responders, will be presented at the 68th ASH Annual Meeting.
Oncolytics Biotech announced translational data from an ongoing Phase 1/2 study of pelareorep in combination with a checkpoint inhibitor for squamous cell anal cancer (SCAC). The data showed that the treatment more than doubled immune activation levels in nearly all patients and expanded HPV-16-specific T cell clones, which was associated with tumor shrinkage and objective responses.
Oncolytics Biotech announced updated data from Cohort 4 of its Phase 1/2 GOBLET study evaluating pelareorep in combination with atezolizumab for squamous cell anal cancer (SCAC). The study demonstrated a median duration of response of approximately 15 months, with 100% of responding patients surviving longer than one year, supporting a potential registration path in HPV-driven cancers.
Oncolytics Biotech announced it will present a trial-in-progress abstract and e-poster for its REO 033 study at the ESMO Congress 2026. The study is a randomized Phase 2 trial evaluating pelareorep in combination with FOLFIRI and bevacizumab for second-line treatment of RAS-mutant, microsatellite-stable metastatic colorectal cancer.